实验室检测在继发性卒中预防中对高凝状态的治疗价值。
The therapeutic value of laboratory testing for hypercoagulable states in secondary stroke prevention.
作者信息
Kalaria Chandni, Kittner Steven
机构信息
Department of Neurology, University of Maryland School of Medicine, 110 South Paca Street, Baltimore, MD 21201, USA.
Department of Neurology, University of Maryland School of Medicine, 110 South Paca Street, Baltimore, MD 21201, USA; Department of Neurology, Baltimore Veterans Administration Medical Center, 100 North Greene Street, Baltimore, MD 21201, USA.
出版信息
Neurol Clin. 2015 May;33(2):501-13. doi: 10.1016/j.ncl.2015.01.003. Epub 2015 Feb 28.
Although screening for hypercoagulable states is commonly performed as part of the evaluation of first arterial ischemic stroke in young adults, available evidence does not support this as a routine practice, even in patients with cryptogenic stroke and a positive family history of early thrombotic events or in patients with a patent foramen ovale. Testing for antiphospholipid antibodies is a possible exception because persistent antibodies are associated with an increased risk of recurrent stroke. Despite the lack of supporting data, screening for hypercoagulable states in recurrent early-onset cryptogenic cerebral ischemia could be considered.
尽管对高凝状态进行筛查通常是评估年轻成人首次动脉缺血性卒中的一部分，但现有证据并不支持将其作为常规做法，即使是对于不明原因卒中且有早期血栓形成事件家族史阳性的患者，或有卵圆孔未闭的患者。抗磷脂抗体检测可能是个例外，因为持续存在的抗体会增加复发性卒中的风险。尽管缺乏支持数据，但对于复发性早发性不明原因脑缺血，可考虑对高凝状态进行筛查。
Zotero 插件